Method for augmenting the effects of serotonin reuptake inhibitors
AssigneeDuke University
InventorsRanga Krishnan, Marc Caron, Xiaodong Zhang, Martin Beaulieu, Raul Gainetdinova, Tatiana Sotnikova
Life of this patent
Estimating the term…
Abstract
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.
Claims73
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprising:
- administering said subject a serotonin reuptake inhibitor in an amount effective to treat said disorder;
- and
- concurrently administering said subject 5-hydroxytryptophan in an amount effective to enhance the activity of said selective serotonin reuptake inhibitor;
- wherein said disorder is selected from the group consisting of depression, anxiety, and substance abuse.
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprising:
- administering said subject a serotonin reuptake inhibitor in an amount effective to treat said disorder;
- and
- concurrently administering said subject a peripheral decarboxylase inhibitor in an amount effective to enhance the activity of said selective serotonin reuptake inhibitor;
- wherein said disorder is selected from the group consisting of depression, anxiety, and substance abuse.
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprising:
- administering said subject a serotonin reuptake inhibitor in an amount effective to treat said disorder;
- and
- concurrently administering said subject tetrahydrobiopterin in an amount effective to enhance the activity of said selective serotonin reuptake inhibitor;
- wherein said disorder is selected from the group consisting of depression, anxiety, and substance abuse.
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprising:
- determining the presence or absence of at least one Tph2 mutation in said subject;
- and then, if said subject possesses at least one Tph2 mutation;
- administering said subject 5-hydroxytryptophan in an amount effective to treat said disorder;
- wherein said disorder is selected from the group consisting of depression, anxiety, and substance abuse.
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprising:
- determining the presence or absence of at least one Tph2 mutation in said subject;
- and then, if said subject possesses at least one Tph2 mutation;
- administering said subject a peripheral decarboxylase inhibitor in an amount effective to treat said disorder;
- wherein said disorder is selected from the group consisting of depression, anxiety, and substance abuse.
A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprising:
- determining the presence or absence of at least one Tph2 mutation in said subject;
- and then, if said subject possesses at least one Tph2 mutation;
- administering said subject tetrahydrobiopterin in an amount effective to treat said disorder;
- wherein said disorder is selected from the group consisting of depression, anxiety, and substance abuse.
A pharmaceutical formulation consisting essentially of:
- (a) from 0.001 to 40 percent by weight serotonin reuptake inhibitor;
- (b) from 0.01 to 60 percent by weight of 5-hydroxytryptophan;
- (c) from 0 to 40 percent by weight of a peripheral decarboxylase inhibitor;
- (d) from 0 to 40 percent by weight of tetrahydrobiopterin;
- and
- (e) from 1 to 99.9 percent by weight of a pharmaceutically acceptable carrier.
A pharmaceutical formulation consisting essentially of:
- (a) from 0.001 to 40 percent by weight serotonin reuptake inhibitor;
- (b) from 0.001 to 40 percent by weight of decarboxylase inhibitor;
- (c) from 0 to 40 percent by weight of tetrahydrobiopterin;
- (d) from 0 to 40 percent by weight of a serotonin precursor;
- and
- (e) from 1 to 99.9 percent by weight of a pharmaceutically acceptable carrier.
A pharmaceutical formulation consisting essentially of:
- (a) from 0.001 to 40 percent by weight serotonin reuptake inhibitor;
- (b) from 0.01 to 60 percent by weight of tetrahydrobiopterin;
- (c) from 0 to 40 percent by weight of a peripheral decarboxylase inhibitor;
- (d) from 0 to 60 percent by weight of a serotonin precursor;
- and
- (e) from 1 to 99.9 percent by weight of a pharmaceutically acceptable carrier.
A pharmaceutical formulation consisting essentially of:
- (a) from 0.01 to 60 percent by weight 5-hydroxytryptophan;
- and
- (b) from 0.001 to 40 percent by weight of decarboxylase inhibitor;
- (c) from 1 to 99.9 percent by weight of a pharmaceutically acceptable carrier.
A pharmaceutical formulation consisting essentially of:
- (a) from 0.1 to 60 percent by weight of a serotonin precursor;
- (b) from 0.1 to 60 percent by weight of tetrahydrobiopterin;
- and
- (c) from 1 to 99.9 percent by weight of a pharmaceutically acceptable carrier.
The use of 5-hydroxytryptophan for the preparation of a medicament for carrying out a method of as described herein.
The use of a peripheral decarboxylase inhibitor for the preparation of a medicament for carrying out a method as described herein.
The use of a serotonin reuptake inhibitor for the preparation of a medicament for carrying out a method as described herein.
The use of tetrahydrobiopterin for the preparation of a medicament for carrying out a method as described herein.
The use of a means for detecting a Tph2 mutation for carrying out a method as described herein.
Dependencies are inferred from the claim text.